- Home
- HURN vs NAMS Comparison
HURN vs NAMS Comparison
Compare HURN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- NAMS
- Stock Information
- Founded
- HURN 2002
- NAMS 2019
- Country
- HURN United States
- NAMS Netherlands
- Employees
- HURN N/A
- NAMS N/A
- Industry
- HURN Professional Services
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- NAMS Health Care
- Exchange
- HURN Nasdaq
- NAMS Nasdaq
- Market Cap
- HURN 2.6B
- NAMS 3.1B
- IPO Year
- HURN 2004
- NAMS N/A
- Fundamental
- Price
- HURN $162.00
- NAMS $35.51
- Analyst Decision
- HURN Strong Buy
- NAMS Strong Buy
- Analyst Count
- HURN 4
- NAMS 10
- Target Price
- HURN $171.50
- NAMS $43.70
- AVG Volume (30 Days)
- HURN 155.2K
- NAMS 1.4M
- Earning Date
- HURN 10-28-2025
- NAMS 11-06-2025
- Dividend Yield
- HURN N/A
- NAMS N/A
- EPS Growth
- HURN 37.96
- NAMS N/A
- EPS
- HURN 5.74
- NAMS N/A
- Revenue
- HURN $1,556,665,000.00
- NAMS $64,006,000.00
- Revenue This Year
- HURN $13.32
- NAMS N/A
- Revenue Next Year
- HURN $8.31
- NAMS N/A
- P/E Ratio
- HURN $26.56
- NAMS N/A
- Revenue Growth
- HURN 9.24
- NAMS 762.15
- 52 Week Low
- HURN $103.24
- NAMS $14.06
- 52 Week High
- HURN $155.38
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- HURN 73.41
- NAMS 57.35
- Support Level
- HURN $150.49
- NAMS $34.34
- Resistance Level
- HURN $155.30
- NAMS $37.21
- Average True Range (ATR)
- HURN 3.54
- NAMS 2.42
- MACD
- HURN 0.50
- NAMS -0.42
- Stochastic Oscillator
- HURN 100.00
- NAMS 34.45
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.